Literature DB >> 2834734

Cell-surface changes associated with transformation of human hepatocytes to the malignant phenotype.

B Wilson1, M Ozturk, H Takahashi, P Motté, M Kew, K J Isselbacher, J R Wands.   

Abstract

Hepatocellular carcinoma is one of the leading causes of cancer death in the world. To understand the cellular changes associated with transformation of hepatocytes to the malignant state, we have made several libraries of monoclonal antibodies against the hepatocellular carcinoma cell line FOCUS and have found six antibodies (AF-20, SF-25, SF-31, SF-90, XF-4, and XF-8) that recognize antigens expressed at consistently higher levels on hepatoma cells. We have studied malignant and nontransformed liver tissue from the same individual by using direct 125I-labeled antibody binding and immunoperoxidase staining techniques. For each of these antibodies, we found striking increases in antigen expression on the transformed tissues. These antigens were found to be expressed throughout the tumor and on distant metastases, with little, if any, expression on the nontransformed adjacent liver. These antibodies demonstrate that hepatic transformation may be accompanied by stereotyped and predictable antigenic changes. The uniformity of such antigenic changes suggests an association between these cell-surface alterations and the malignant transformation process.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834734      PMCID: PMC280159          DOI: 10.1073/pnas.85.9.3140

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  Tight clustering of human hepatitis B virus integration sites in hepatomas near a triple-stranded region.

Authors:  C Shih; K Burke; M J Chou; J B Zeldis; C S Yang; C S Lee; K J Isselbacher; J R Wands; H M Goodman
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  A target structure for a series of human cloned natural killer cell lines is recognized by both anti-TNKtar and 4F2 monoclonal antibodies.

Authors:  P Moingeon; A Nowill; G Courtois; B Azzarone; P Motte; A Ythier; C Bohuon; T Hercend
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

5.  High affinity monoclonal antibodies to hepatitis B surface antigen (HBsAg) produced by somatic cell hybrids.

Authors:  J R Wands; V R Zurawski
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

6.  Human hepatoma-associated cell surface antigen: identification and characterization by means of monoclonal antibodies.

Authors:  D Shouval; D Eilat; R I Carlson; R Adler; N Livni; J R Wands
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

7.  Establishment and characterization of a new human hepatocellular carcinoma cell line.

Authors:  L He; K J Isselbacher; J R Wands; H M Goodman; C Shih; A Quaroni
Journal:  In Vitro       Date:  1984-06

8.  Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal antibodies.

Authors:  R I Carlson; E Ben-Porath; D Shouval; W Strauss; K J Isselbacher; J R Wands
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

9.  Human hepatocellular carcinoma: cross-reactive and idiotypic antigens associated with malignant transformation of epithelial cells.

Authors:  K H Wiedmann; L K Trejdosiewicz; J Southgate; H C Thomas
Journal:  Hepatology       Date:  1987 May-Jun       Impact factor: 17.425

10.  Identification of human hepatoma-defined cell surface molecules.

Authors:  D M Moriarity; N Fox; D P Aden; J R Hoyer; B B Knowles
Journal:  Hybridoma       Date:  1983
View more
  7 in total

1.  Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma.

Authors:  M Frohlich; P Motté; K Galvin; H Takahashi; J Wands; M Ozturk
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

2.  Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma.

Authors:  L Lavaissiere; S Jia; M Nishiyama; S de la Monte; A M Stern; J R Wands; P A Friedman
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

3.  Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration.

Authors:  Suzanne M de la Monte; Ming Tong; Rolf I Carlson; Jade J Carter; Lisa Longato; Elizabeth Silbermann; Jack R Wands
Journal:  Alcohol       Date:  2009-05       Impact factor: 2.405

4.  Impaired placentation in fetal alcohol syndrome.

Authors:  F Gundogan; G Elwood; L Longato; M Tong; A Feijoo; R I Carlson; J R Wands; S M de la Monte
Journal:  Placenta       Date:  2007-12-03       Impact factor: 3.481

5.  Identification of Tumor Antigen AF20 as Glycosylated Transferrin Receptor 1 in Complex with Heat Shock Protein 90 and/or Transporting ATPase.

Authors:  Jason M Shapiro; Waihong Chung; Kosuke Ogawa; Luke Barker; Rolf Carlson; Jack R Wands; Jisu Li
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

6.  Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen.

Authors:  Michael Babich; Ankit Sharma; Tianhong Li; James A Radosevich
Journal:  Heliyon       Date:  2022-02-21

7.  Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2.

Authors:  Giulia Pellizzari; Olivier Martinez; Silvia Crescioli; Robert Page; Ashley Di Meo; Silvia Mele; Giulia Chiaruttini; Jan Hoinka; Ihor Batruch; Ioannis Prassas; Melanie Grandits; Jacobo López-Abente; Eva Bugallo-Blanco; Malcolm Ward; Heather J Bax; Elise French; Anthony Cheung; Sara Lombardi; Mariangela Figini; Katie E Lacy; Eleftherios P Diamandis; Debra H Josephs; James Spicer; Sophie Papa; Sophia N Karagiannis
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.